Trial Profile
To assess clinical factors related to the efficacy of tyrosine kinase inhibitor therapy lenvatinib in recurrent radioiodine-refractory differentiated thyroid cancer (RR-DTC) patients and identify the optimal timing for the start of TKI therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Oct 2018
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 12 Oct 2018 New trial record